Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection
Xiuning Le,Frederico O Gleber-Netto,M Laura Rubin,Yun Qing,Robyn Du,Merrill Kies,George Blumenschein,Charles Lu,Faye M Johnson,Diana Bell,Jeff Lewis,Jiexin Zhang,Lei Feng,Kaye Wilson,Kathrina Marcelo-Lewis,Jing Wang,Lawrence Ginsberg,Maura Gillison,J Jack Lee,Funda Meric-Bernstam,Gordon B Mills,William N William,Jeffrey N Myers,Curtis R Pickering,Frederico O. Gleber-Netto,M. Laura. Rubin,George Blumenschein, Jr,Faye M. Johnson,J. Jack. Lee,Gordon B. Mills,William N. William,Jeffrey N. Myers,Curtis R. Pickering
DOI: https://doi.org/10.1158/1078-0432.ccr-21-3239
IF: 13.801
2022-04-20
Clinical Cancer Research
Abstract:Abstract Purpose: Neoadjuvant chemotherapy prior to definitive surgery has been utilized widely for locally advanced oral squamous cell carcinoma (OSCC). We evaluated neoadjuvant erlotinib with platinum-docetaxel vs. placebo with platinum-docetaxel in stage III-IVB OSCC patients. Experimental Design: Patients with newly diagnosed stage III, IVA, IVB (AJCC 7th) OSCC amenable to surgical resection were included. Patients were randomized to receive up to 3 cycles of chemotherapy with concurrent erlotinib or placebo, followed by surgery. The primary endpoint was major pathologic response (MPR) rate, secondary endpoints included safety, overall (OS) and progression-free survival (PFS). Results: Fifty-two patients received at least one cycle of treatment and 47 were evaluable with surgical resection. MPR rate was not different between erlotinib (30%, 7/23) and placebo arms (41.7%, 10/24) (p=0.55). At median follow up of 26.5 months, there was no difference on OS or PFS between groups. Patients who received erlotinib with chemotherapy and achieved MPR (n=7) had no recurrence. The treatment-related adverse event rates were not different between the two groups (96% vs. 96%). However, rash, mostly low grade, was more common in the erlotinib arm (79% vs. 50%). Transcriptomic analysis in the pre-treatment samples indicated that genes in protein glycosylation and Wnt signaling pathways were associated with benefit in those treated with erlotinib plus chemotherapy. Conclusions: The addition of erlotinib to platinum-taxane chemotherapy was well-tolerated but did not induce higher rates of MPR or PFS or OS survival benefit. Patients who received chemotherapy with erlotinib and achieved major pathological responses had excellent clinical outcome.
oncology